Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on ADPT since May 5, 2026, most recently "Adaptive Biotechnologies (NASDAQ:ADPT) Raises FY2026 MRD Guidance After Q2 Beat" on Wednesday, July 29, 2026. Coverage to date spans Earnings Report, tracking ADPT's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
ADPT posted Q2 EPS of -$0.10 vs. -$0.14 consensus, with MRD revenue up 33% YoY. Full-year MRD guidance raised to $268M-$278M.
ADPT reported a Q1 2026 net loss of $20M, or $0.13 per share, as shares fell 4.97%. Revenue growth of 51% YoY underscores the company's commercial momentum.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.